FDA Extends Review Period Of Ruxolitinib Cream For Pediatric Patients With Atopic Dermatitis To September
- June 23, 2025
You must be logged in to access this content.
Cookie Consent
This site uses cookies to store information on your computer. Without consent certain enhanced features will not be available and future visits may require repeated consent, so it is recommended to accept the use of cookies. Visit the AHLA Privacy Policy for more information.
Health Law Daily